Compare CCM & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCM | PLUR |
|---|---|---|
| Founded | 1997 | 2001 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.3M | 18.5M |
| IPO Year | 2009 | 2001 |
| Metric | CCM | PLUR |
|---|---|---|
| Price | $4.69 | $1.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 74.4K | 22.8K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,336,000.00 |
| Revenue This Year | N/A | $97.38 |
| Revenue Next Year | N/A | $293.97 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 309.82 |
| 52 Week Low | $3.18 | $1.38 |
| 52 Week High | $6.98 | $5.17 |
| Indicator | CCM | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 46.98 | 35.57 |
| Support Level | $4.41 | N/A |
| Resistance Level | $5.43 | $1.85 |
| Average True Range (ATR) | 0.41 | 0.12 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 17.12 | 4.35 |
Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Geographically, the company derives revenue from PRC.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.